Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers andto characterize their molecular relevance to MYC.
The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.
- Howard-Temin Pathway to Independence Award (R00), NCI.
- Department of Pharmacology & Experimental Therapeutics and Cancer Center, BUSM.
- American Cancer Society.
- Hematology Training Grant, NHLBI.
- UROP, SURP, RISE, Boston University.